We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01985399
Recruitment Status : Completed
First Posted : November 15, 2013
Last Update Posted : October 17, 2016
Information provided by (Responsible Party):

November 4, 2013
November 15, 2013
October 17, 2016
December 2013
December 2015   (Final data collection date for primary outcome measure)
Compare a composite measure of neurocognitive function in older individuals on EFV-containing ART vs. non-EFV-containing ART. [ Time Frame: one year ]

Neurocognitive function will be assessed using a detailed battery of neuropsychologic tests including timed gait, grooved pegboard with the dominant and non-dominant hands, the Rey auditory verbal learning test trials I-VII, trail making parts A and B, Rey auditory verbal learning test trial VIII 30-min delay, controlled oral word association test and paced auditory serial addition task. This battery has been used extensively in previous studies in HIV. Z-scores for each neurocognitive test, based on age-adjusted norms, and a composite Z-score will be calculated. The Z-score represents the amount, in standard deviation units, that the subject's test result deviates from population means.

In addition to neurocognitive function, the level of depression and anxiety and sleep quality will be evaluated using validated instruments.

Same as current
Complete list of historical versions of study NCT01985399 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")
Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")
Investigators hypothesize that older HIV-infected individuals (i.e., >50 years old) on efavirenz (EFV)-containing antiretroviral therapy (ART) will have significantly worse neurocognitive function than older individuals on non-EFV-containing ART.

With the aging of the HIV-infected population in the United States and elsewhere, neurocognitive dysfunction will likely become an increasingly common problem. Older individuals could be at increased risk for efavirenz-associated adverse effects due to impaired metabolism, increased drug-drug interactions, and lower physiologic reserve, but there are few data on the long-term safety of efavirenz (and other antiretrovirals) in older individuals with HIV.

The Stanford HIV Aging Cohort (SHAC) is an ideal setting to study potential neurologic effects of antiretrovirals in aging patients. SHAC is an ongoing longitudinal study initiated in 2008 to evaluate aging in virologically-suppressed HIV-infected individuals. The cohort is supported through multiple grants including a grant from the State of California's HIV Research Program as well as a NIH supplemental grant. As of September 2013, approximately 150 virologically-suppressed HIV-infected adults have been enrolled. In addition to enrolling patients with good adherence to ART, the cohort purposefully excludes subjects with active substance abuse, unstable medical conditions, and psychiatric illnesses to limit potential confounding the study end points. Recently, an NIH supplemental grant (AI069556) was received which will expand the SHAC to 300 HIV-infected subjects. The median age of the subjects in the cohort is in the mid-50's allowing an ample number of older subjects for our planned studies.

Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
50 individuals on an EFV-containing regimen and 50 individuals on a protease-inhibitor (PI)-containing regimen
  • HIV
  • AIDS
Behavioral: Neuropsychological testing
Neuropsychological testing
  • EFV containing ARV regimen
    Pts on Efavirenz containing ARV regimen will have neuropsychological testing performed
    Intervention: Behavioral: Neuropsychological testing
  • Non -EFV ontaning ARV regimen
    Pts on a Non-Efavirenz containing ARVregimen will have neuropsychological testing measures performed
    Intervention: Behavioral: Neuropsychological testing
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2015
December 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Enrollment into SHAC (Stanford HIV Aging cohort)
  • Age over 50 years of age
  • Stable antiretroviral therapy containing EFV- or PI-containing ART (but not both) for at least 6 months
  • HIV RNA levels of <200 copies/mL for at least 6 months excluding blips (i.e., a single measurement between 200-500 copies/mL preceded and followed by measurements of <200 copies/mL) while on ART.

Exclusion Criteria:

  • Completed treatment for any acute systemic infection (other than HIV-1) less than four weeks before study entry
  • Any active brain infection (except for HIV-1), brain neoplasm, or space-occupying brain lesion.
  • Any active psychiatric illness including schizophrenia, severe depression, or severe bipolar affective disorder that, in the opinion of the investigator, could confound the analysis of the neuropsychological test results.
  • Active drug or alcohol abuse that, in the investigator's opinion, could prevent compliance with study procedures or confound the analysis of study endpoints.
  • Hospitalization within 30 days of study entry
  • Receipt of systemic chemotherapy within 30 days of study entry
  • Unable to provide informed consent
Sexes Eligible for Study: All
50 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
SHAC Neuro Study
Not Provided
Not Provided
Philip Grant, Stanford University
Stanford University
Janssen Services, LLC
Principal Investigator: Philip Grant, MD Stanford University
Stanford University
October 2016